

## Goals of ASAM's 2020 Cannabis Policy

- Present a scientifically valid background on the most important and consistent findings
- Provide recommendations for cannabis for medical purposes which are consistent with sound medical practice
- Provide recommendations for cannabis for non-medical purposes which will reduce potential harms (“We’re not opposed to any legalization; we are opposed to reckless legalization.” )
- Be invited to participate when policies are written

# Representative Recommendations from ASAM's Cannabis Policy

## Medical Purposes (11 total):

- Reschedule from Schedule 1 to promote more clinical research and regulatory oversight (e.g., FDA)
- Healthcare professionals who authorize non-FDA-approved cannabis should do so in the context of an ongoing patient-clinician relationship.
- Oversight of cannabis for medical purposes should come from state health departments.

## Non-Medical Purposes (13 total):

- CSA should be amended so that in states which comply with sound public health measures, citizens are exempt from penalties.
- Cannabis production, distribution, and sale should not be commercialized.
- Evidence-based prevention programs should be strengthened, potency of cannabis should be limited, and persons at high risk of harm should be identified.